Worth reading
36Immaterial
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
5.3
%Wording
Avoiding a definitive answer
How definitive the wording is.Results for this period
Interim period (second quarter)2024年4月1日〜2024年9月30日Non-consolidated (standalone)Japanese GAAPNet Sales3,811¥ millionYear on year +5.3%
Operating profit-276¥ million
Ordinary income-256¥ million
Net income attributable to owners of the parent-141¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Net income per share△4.08円
Financial position at period-end
Total assets15,256¥ million
of which net assets 11,946 ¥ millionEquity ratio 78.3%vs. prior year-end +0.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+282,579
Investment-225,179
Financials-103,877
Net change-46,477
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥3,618,168 thousand
Segment revenuePharmaceuticals ¥1,553,185 thousand (YoY -4.4%), Healthcare Business ¥1,263,192 thousand (YoY +17.5%), Global Business ¥905,203 thousand (YoY +8.8%), Real estate leasing ¥89,418 thousand (YoY +3.7%)
Segment profitPharmaceuticals ¥-644,309 thousand, Healthcare Business ¥230,289 thousand, Global Business ¥106,293 thousand, Real estate leasing ¥31,044 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net SalesUndecided
Operating profitUndecided
Ordinary incomeUndecided
Net incomeUndecided
Annual Dividend Forecast¥3 → Undecided
Factors Behind Changes in Business Performance
医薬事業における製品供給停止の影響等による減少があったが、ヘルスケア事業における主力製品等の増加、グローバル事業における国内用乳酸菌原料の増加により売上高が増加。販売費及び一般管理費は人件費等の増加により増加。
Disclosure regarding the going concern assumption
Not applicable
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Breakdown of extraordinary income (loss)Extraordinary income None / Extraordinary loss Loss on disposal of non-current assets ¥1,936 thousand, Office relocation expenses ¥1,314 thousand
Depreciation and amortization¥206,150 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End34,838,325
Treasury Shares at Period-End131,783
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 2024年4月1日〜2024年9月30日 |
| Net Sales | ¥3,811 million (YoY +5.3%) |
| Operating profit | ¥-276 million |
| Ordinary income | ¥-256 million |
| Profit attributable to owners of the parent | ¥-141 million |
| Net income per share | △4.08円 |
| Equity ratio | End of the current fiscal period 78.3 / End of previous period 78 |
| Total assets | ¥15,256 million |
| Net assets | ¥11,946 million |
| Cash flows from operating activities | ¥282,579 thousand |
| Cash flows from investing activities | ¥-225,179 thousand |
| Cash flows from financing activities | ¥-103,877 thousand |
| Cash and cash equivalents at end of period | ¥3,618,168 thousand |
| Full-year earnings forecast | Net Sales Undecided / Operating profit Undecided / Ordinary income Undecided / Net income Undecided |
| Annual Dividend Forecast | ¥3 → Undecided |
| Segment revenue | Pharmaceuticals ¥1,553,185 thousand (YoY -4.4%), Healthcare Business ¥1,263,192 thousand (YoY +17.5%), Global Business ¥905,203 thousand (YoY +8.8%), Real estate leasing ¥89,418 thousand (YoY +3.7%) |
| Segment profit | Pharmaceuticals ¥-644,309 thousand, Healthcare Business ¥230,289 thousand, Global Business ¥106,293 thousand, Real estate leasing ¥31,044 thousand |
| Depreciation and amortization | ¥206,150 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income None / Extraordinary loss Loss on disposal of non-current assets ¥1,936 thousand, Office relocation expenses ¥1,314 thousand |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 34,838,325 |
| Treasury Shares at Period-End | 131,783 |
| Factors Behind Changes in Business Performance | 医薬事業における製品供給停止の影響等による減少があったが、ヘルスケア事業における主力製品等の増加、グローバル事業における国内用乳酸菌原料の増加により売上高が増加。販売費及び一般管理費は人件費等の増加により増加。 |
Items this document does not state (9)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossChanges in the scope of consolidationMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.医薬事業では製品供給停止の影響などで減収となりましたが、ヘルスケア事業の主力製品等やグローバル事業の国内用乳酸菌原料が増加しました。売上総利益は増加した一方、人件費等の増加により販売費及び一般管理費も増加しました。通期予想は、マキュエイド眼注用40mgの供給停止について影響額の正確な把握が困難なため未定としています。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.